Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins;Neoplasias astrocitárias e correlação com as proteínas p53 mutada e Ki-67

Arquivos de Neuro-Psiquiatria

Volumn 63, Issue 4, 2005, Pages 997-1004

  Isolan, Gustavo Rassier ^a,b,f   Ribas Filho, Jurandir Marcondes ^a,c   Isolan, Paola Maria B S ^a   Giovanini, Allan ^a,d,e   Malafaia, Osvaldo ^a,f   Dini, L I ^a   Kummer Jr , Arthur ^a,g   Negrão, Alexandre W ^a,b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b IPEM   (Brazil)

^c FEPAR   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNICENP   (Brazil)

^f UNICENP ^*  (Brazil)

^g Departamento de Neurocirurgia do HUEC

Author keywords

Astrocytoma; Ki 67; p53

Indexed keywords

KI 67 ANTIGEN; MUTANT PROTEIN; PROTEIN P53; TUMOR MARKER;

AGE DISTRIBUTION; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURGERY; CELL NUCLEUS; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE; WORLD HEALTH ORGANIZATION;

EID: 32244435552     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/s0004-282x2005000600017     Document Type: Article

References (33)

1. De Angelis LM. Brain tumor. N Engl J Med 2001;344:114-123.
2. Shiraishi S. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 2002;95:249-257.
3. Yonish-rouach E. Aquestion of lie or death: the p53 tumor suppressor gene. Pathol Biol 1997;45:815-823.
4. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system: World Health Organization classification of tumors. Lyon: LARC Press, 2000.
5. Baserga R. Oncogene and the strategy of growth. Cell 1994;79:927-939.
6. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of anaplastic astrocytomas. J Neurooncol 2002;58:203-215.
7. Kurtkaia-yapicier Ö, Scheithauer BW, Hebrink D, James CD. p53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study. Neurosurgery 2002;51:1246-1255.
8. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell Physiol 2000;182:311-322.
9. Matsumoto T, Fujii T, Yabe M, Oka K, Hoshi T, Sato K. MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults. Histopathology 1998;33:446-452.
10. McKeever PE, Strawderman MS, Yamini B, Mikhail AA, Blaivas M. MIB-1 proliferation index predicts survival among with grau II astrocytoma. J Neuropathol Exp Neurol 1998;57:931-936.
11. Hara A, Saegusa M, Mikami T, Okayasu I. Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival. J Clin Pathol 2001;54:860-865.
12. Kayaselcuk F, Zorludemir S, Gumurduhu D, Zeren H, Erman T. PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grau. J. Neurooncol 2002;57:115-121.
13. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity on chromosome 17 and 10 during human astrocytic progression. Cancer Res 1992;42:674-679.
14. Sidransky D. Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Volgestein B. Clonal expansion of p53 cells is associated with brain tumor progression. Nature 1992;355:846-847.
15. Louis DN, Cavenee WK. Molecular biology of central nervous system tumors. Disponível em:〈http://brain.mgh.harvard.edu/moleculargenetics. htm〉 Acesso em: 01 mar. 2003.
16. Barbareschi M, Luzzolino P, Pennella A. p53 protein expression in central nervous system neoplasms. J Clin Pathol 1992;45:583-586.
17. Ellison DW, Gatter KC, Steart PV, Lane DP, Weller RO. Expression of the p53 protein in a spectrum of astrocytic tumors. J Pathol 1992;168:383-386.
18. Vital A, Loiseau H, Kantor G, et al. p53 protein expression in grau II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up. Pathol Res Pract 1998;194:831-836.
19. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry? Revisited. J Pathol 1994;172:1-4.
20. Litofsky NS, Recht LD. The impact of p53 tumor suppressor gene on glioma biology. Neurosurg Focus 1997;3:3.
21. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patient with multiple biopsies. Clin Cancer Res 1997;3:523-530.
22. Shields PG, Harris CC. Molecular epidemiology and the genetics of environmental cancer. JAMA 1991;266:681-687.
23. Darnton E. Demystified...p53. Mol Pathol 1998;51:248-253.
24. Das A, Tan WL, Teo J, Smith DR. Glioblastoma multiforme in an Asian population: evidence for distinct genetic pathway. J Neurooncol 2002;60:117-125.
25. Kordek R, Biernat W, Debiec-Rychter, Alwasiak J, Liberski PP. Comparative evalution of p53-protein expression and the PCNA and Ki-67 proliferating cell indices in human astrocytomas. Pathol Res Pract 1996;192:205-209.
26. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB. Analysis of proliferation and p53 expression in gliomas of astrocytic orign: relationships and prognostic value. J Neurosurg 1997;86:21-30.
27. Sarkar C, Chattopadhyay P, Ralte AM, Mahapatra AK, Sinha S. Loss of heterozygosity of a locus in the chromossomal region 17p13.3 is associated with increased cell proliferation in astrocytic tumors. Cancer Genet Cytogenet 2003;144:56-64.
28. Litofsky NS, Hinton D, Raffel C. The lack of a role p53 in astrocytomas in pediatric patients. Neurosurgery 1994;34:967-973.
29. Jaros E, Perry RH, Adam L, et al. Prognostic implications of p53 protein, ephidermal growth factor receptor, and Ki-67 labelling in brain tumors. Br J Cancer 1992;66:373-385.
30. Schiffer D, Chio A, Giordana MT, Leone M, Soffietti R. Prognostic value of histologic factors in adult cerebral astrocytoma. Cancer 1988;61:386-393.
31. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW. High frequency of p53 protein accumulation without gene mutation in human juvenile pilocytic, low grau and anaplastic astrocytomas. Oncogene 1994;9:949-954.
32. Pollack IF, Hamilton RL, Finkelstein SD, et al. The relationship between TP53 mutation and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997;57:304-309.
33. Pollack IF, Finkelstein SD, Burnham J, et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res 2001;61:7404-7407.